Article
The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.
All News
Article
A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.
Article
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Article
While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.
Article
Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.
Article
Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.
Article
A single ultrasound guided intra-articular hip corticosteroid injection can be quite effective in patients with hip osteoarthritis (OA).
Article
An evaluation of a common psoriasis drug's effect on one cardiometabolic risk factor instead showed a favorable impact on a different one.
Article
With overwhelming support from some 200 experts worldwide, dosing of methotrexate (MTX) for psoriasis should start at 15 mg/week for most adults, though lower in those considered "vulnerable" and in children, according to a new consensus statement.
Article
Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss key advances and modern disease management. We're featuring guest bloggers, hosting Tuesday Night Rheumatology, posting slides and videos, and much more dedicated to PsA.
Dr. John Cush
Tweet
Open label, RCT compared triple DMARD Rx adding either LEF (MLH) or SSZ (MSH) to MTX+HCQ in 136 RA pts. Both were equally effective (non-inferior), 61.7% & 64.7% patients (p = 0.8) at wk 24. AE were also equal (15 vs 21 AE). https://t.co/cxdeBfo6XA
Dr. John Cush
Tweet
Administrative Claims data from British Columbia studied 100,358 OA pts and compared tramadol v NSAIDs. Tramadol was associated with higher All-cause mortality (HRs,1.2 to 1.5), more VTE (v diclofenac, HR 1.7), more hip Fx (HR 1.6) https://t.co/5Lei6Lgtpf
Dr. John Cush
Tweet
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA
37 RCTs = 14.115 PsA pts
◾️ bDMARDs > PBO
◾️ bDMARDs = MTX (or Tofa)
◾️ bDMARDs + MTX > MTX
https://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK
Dr. John Cush
Tweet
Comparison of Tofa, ADA, PBO in OPAL #PSA studies - median time to HAQ response better for Tofa & ADA (30d) vs PBO (>112d), but Tofa had faster Fatigue response (31 vs 90+D). MDA response time same between Tofa v ADA #PSAlways https://t.co/f48Of7bEjN https://t.co/KvfQUbLwCH
Dr. John Cush
Tweet
ArthritisPower study of 332 #PsA pts finds patients are most bothered by joint pain, MSK pain & fatigue. Patients prefer oral, QD meds; 3/4 want Rx that improved joints vs skin; and would prefer to avoid MTX https://t.co/WYqWgoimOT https://t.co/RgGeCKrpT1
Dr. John Cush
Tweet
CorEvitas Registry study of Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted in modest, nonsignificant improvement axial outcomes,(irrespective HLA-B27 status), including ASDAS40, BASDAI50, & spinal pain. 31% of pts were B27+ https://t.co/9m9H7PwIIF #PsAlways https://t.co/dYk5GfIdez
Dr. John Cush
Tweet
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0
Dr. John Cush
Tweet
Czech registry compared drug survival csDMARDs vs TNFi monotherapy. Drug retention higher w/ combo (47 vs 23 mos; p < 0.001) than TNFi monotherapy. 5 yr survival was better 45% vs 26%; Combo w/ MTX > other csDMARDs (p = 0.003). https://t.co/pjbXwEQ53K https://t.co/nZj64Wk3Pt
Dr. John Cush
Tweet
Towards More Uniform Methotrexate Dosing in Psoriasis
https://t.co/3GrJADizKK https://t.co/jMAQO5D5Zz
Dr. John Cush
Tweet
Your Hot Topic Questions from RNL 2022
Rheumatologists questions for Dr. Jack Cush
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/wpPeIwiCxe https://t.co/UY3gDaVeTv
